Isopropalin is a pre-emergent herbicide used to control broadleaf weeds in various crops, such as soybeans, peanuts, and cotton. Its synthesis involves a multi-step process that begins with the reaction of 2,6-dichloroaniline with 2-methyl-1-propanol. This reaction forms a key intermediate, which is then reacted with isobutylene oxide to yield isopropalin. Isopropalin inhibits the growth of weeds by disrupting the formation of microtubules, which are essential for cell division and growth. It has been found to be effective in controlling a wide range of weed species, including pigweed, ragweed, and crabgrass. Its use in agriculture has been crucial for maintaining crop yields and minimizing weed competition. Due to its effectiveness and environmental impact, isopropalin has been extensively studied to understand its fate and transport in the environment. Researchers investigate its degradation pathways, potential leaching into groundwater, and its effects on non-target organisms. '
isopropalin: structure
ID Source | ID |
---|---|
PubMed CID | 36606 |
CHEMBL ID | 1256728 |
CHEBI ID | 82189 |
SCHEMBL ID | 55296 |
MeSH ID | M0051842 |
Synonym |
---|
4-isopropyl-2,6-dinitro-n,n-dipropylaniline |
brn 2762577 |
paarlan |
epa pesticide chemical code 100201 |
isopropaline [iso-french] |
hsdb 6687 |
cumidine, 2,6-dinitro-n,n-dipropyl- |
2,6-dinitro-n,n-dipropylcumidine |
caswell no. 506a |
el-179 |
aniline, 2,6-dinitro-n,n-dipropyl-p-isopropyl- |
isopropaline |
2,6-dinitro-n,n-dipropyl-4-isopropylaniline |
4-(1-methylethyl)-2,6-dinitro-n,n-dipropylbenzenamine |
isopropalin [ansi:bsi:iso] |
einecs 251-690-7 |
benzenamine, 4-(1-methylethyl)-2,6-dinitro-n,n-dipropyl- |
isopropalin |
33820-53-0 |
(4-isopropyl-2,6-dinitrophenyl)dipropylamine |
4-isopropyl-2,6-dinitro-n,n-dipropyl-aniline |
2,6-dinitro-4-propan-2-yl-n,n-dipropylaniline |
NCGC00248025-02 |
NCGC00248025-01 |
C19063 |
CHEMBL1256728 |
chebi:82189 , |
NCGC00259777-01 |
cas-33820-53-0 |
tox21_300422 |
dtxsid8024157 , |
tox21_202228 |
NCGC00254366-01 |
dtxcid904157 |
unii-52gzd1i41n |
52gzd1i41n , |
AKOS015892015 |
SCHEMBL55296 |
isopropalin [mi] |
isopropalin [hsdb] |
isopropalin [iso] |
NEKOXWSIMFDGMA-UHFFFAOYSA-N |
n-(4-isopropyl-2,6-dinitrophenyl)-n,n-dipropylamine # |
el 179 |
isopropalin, pestanal(r), analytical standard |
isopropalin, analytical standard |
J-019332 |
Q27155794 |
Class | Description |
---|---|
C-nitro compound | A nitro compound having the nitro group (-NO2) attached to a carbon atom. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 2.7306 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
AR protein | Homo sapiens (human) | Potency | 39.3614 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID743035; AID743042; AID743063 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 16.8222 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839 |
progesterone receptor | Homo sapiens (human) | Potency | 33.6434 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 19.0914 | 0.0008 | 17.5051 | 59.3239 | AID1159531 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 67.1274 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 21.5744 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 23.8660 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 7.7752 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1224895 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 64.1290 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID522809 | Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin H28Q mutation infected in HFF cells by plaque assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. |
AID522806 | Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin V4L mutation infected in HFF cells by plaque assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. |
AID522816 | Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin R243S mutation infected in HFF cells by plaque assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. |
AID522812 | Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235T mutation infected in HFF cells by plaque assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. |
AID522810 | Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin L136F mutation infected in HFF cells by plaque assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. |
AID522808 | Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin F24H mutation infected in HFF cells by plaque assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. |
AID522805 | Antimicrobial activity against Toxoplasma gondii RH infected in HFF cells by plaque assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. |
AID522807 | Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin S6I mutation infected in HFF cells by plaque assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. |
AID522813 | Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235V mutation infected in HFF cells by plaque assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. |
AID522811 | Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235L mutation infected in HFF cells by plaque assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. |
AID522815 | Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin R243C mutation infected in HFF cells by plaque assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. |
AID522814 | Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin T239I mutation infected in HFF cells by plaque assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (33.33) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 1 (16.67) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.49) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |